Toll Free: 1-888-928-9744
Published: Mar, 2015 | Pages:
633 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Gastric Cancer - Pipeline Review, H1 2015 Summary Global Markets Direct’s, ‘Gastric Cancer - Pipeline Review, H1 2015’, provides an overview of the Gastric Cancer’s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Gastric Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gastric Cancer and special features on late-stage and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Gastric Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Gastric Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Gastric Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Gastric Cancer pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Gastric Cancer - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Gastric Cancer pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 Introduction 7 Gastric Cancer Overview 8 Therapeutics Development 9 Gastric Cancer - Therapeutics under Development by Companies 11 Gastric Cancer - Therapeutics under Investigation by Universities/Institutes 21 Gastric Cancer - Pipeline Products Glance 23 Gastric Cancer - Products under Development by Companies 27 Gastric Cancer - Products under Investigation by Universities/Institutes 39 Gastric Cancer - Companies Involved in Therapeutics Development 40 Gastric Cancer - Therapeutics Assessment 144 Drug Profiles 164 Gastric Cancer - Recent Pipeline Updates 456 Gastric Cancer - Dormant Projects 595 Gastric Cancer - Discontinued Products 603 Gastric Cancer - Product Development Milestones 606 Appendix 613
List of Tables Number of Products under Development for Gastric Cancer, H1 2015 28 Number of Products under Development for Gastric Cancer - Comparative Analysis, H1 2015 29 Number of Products under Development by Companies, H1 2015 31 Number of Products under Development by Companies, H1 2015 (Contd..1) 32 Number of Products under Development by Companies, H1 2015 (Contd..2) 33 Number of Products under Development by Companies, H1 2015 (Contd..3) 34 Number of Products under Development by Companies, H1 2015 (Contd..4) 35 Number of Products under Development by Companies, H1 2015 (Contd..5) 36 Number of Products under Development by Companies, H1 2015 (Contd..6) 37 Number of Products under Development by Companies, H1 2015 (Contd..7) 38 Number of Products under Development by Companies, H1 2015 (Contd..8) 39 Number of Products under Investigation by Universities/Institutes, H1 2015 41 Comparative Analysis by Late Stage Development, H1 2015 42 Comparative Analysis by Clinical Stage Development, H1 2015 43 Comparative Analysis by Early Stage Development, H1 2015 44 Comparative Analysis by Unknown Stage Development, H1 2015 45 Products under Development by Companies, H1 2015 46 Products under Development by Companies, H1 2015 (Contd..1) 47 Products under Development by Companies, H1 2015 (Contd..2) 48 Products under Development by Companies, H1 2015 (Contd..3) 49 Products under Development by Companies, H1 2015 (Contd..4) 50 Products under Development by Companies, H1 2015 (Contd..5) 51 Products under Development by Companies, H1 2015 (Contd..6) 52 Products under Development by Companies, H1 2015 (Contd..7) 53 Products under Development by Companies, H1 2015 (Contd..8) 54 Products under Development by Companies, H1 2015 (Contd..9) 55 Products under Development by Companies, H1 2015 (Contd..10) 56 Products under Development by Companies, H1 2015 (Contd..11) 57 Products under Investigation by Universities/Institutes, H1 2015 58 Gastric Cancer - Pipeline by AB Science, H1 2015 59 Gastric Cancer - Pipeline by AbbVie Inc., H1 2015 60 Gastric Cancer - Pipeline by AbGenomics International, Inc., H1 2015 61 Gastric Cancer - Pipeline by Advaxis, Inc., H1 2015 62 Gastric Cancer - Pipeline by Advenchen Laboratories, LLC, H1 2015 63 Gastric Cancer - Pipeline by Ambrx, Inc., H1 2015 64 Gastric Cancer - Pipeline by Amgen Inc., H1 2015 65 Gastric Cancer - Pipeline by Aslan Pharmaceuticals Pte. Ltd., H1 2015 66 Gastric Cancer - Pipeline by Astellas Pharma Inc., H1 2015 67 Gastric Cancer - Pipeline by AstraZeneca PLC, H1 2015 68 Gastric Cancer - Pipeline by AVEO Pharmaceuticals, Inc., H1 2015 69 Gastric Cancer - Pipeline by Avipep Pty Ltd, H1 2015 70 Gastric Cancer - Pipeline by Azaya Therapeutics Incorporated, H1 2015 71 Gastric Cancer - Pipeline by Basilea Pharmaceutica AG, H1 2015 72 Gastric Cancer - Pipeline by Bayer AG, H1 2015 73 Gastric Cancer - Pipeline by Bellicum Pharmaceuticals, Inc., H1 2015 74 Gastric Cancer - Pipeline by BioMarin Pharmaceutical Inc., H1 2015 75 Gastric Cancer - Pipeline by Biotecnol, Inc., H1 2015 76 Gastric Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2015 77 Gastric Cancer - Pipeline by Boston Biomedical, Inc., H1 2015 78 Gastric Cancer - Pipeline by Bristol-Myers Squibb Company, H1 2015 79 Gastric Cancer - Pipeline by cCAM Biotherapeutics Ltd., H1 2015 80 Gastric Cancer - Pipeline by Celgene Corporation, H1 2015 81 Gastric Cancer - Pipeline by Cellectar Biosciences, Inc., H1 2015 82 Gastric Cancer - Pipeline by Celltrion, Inc., H1 2015 83 Gastric Cancer - Pipeline by Celon Pharma Sp. z o.o., H1 2015 84 Gastric Cancer - Pipeline by Cerulean Pharma, Inc., H1 2015 85 Gastric Cancer - Pipeline by Chipscreen Biosciences Ltd, H1 2015 86 Gastric Cancer - Pipeline by Chugai Pharmaceutical Co., Ltd., H1 2015 87 Gastric Cancer - Pipeline by Covagen AG, H1 2015 88 Gastric Cancer - Pipeline by DAE HWA Pharmaceutical Co., Ltd., H1 2015 89 Gastric Cancer - Pipeline by Daiichi Sankyo Company, Limited, H1 2015 90 Gastric Cancer - Pipeline by Deciphera Pharmaceuticals, LLC, H1 2015 91 Gastric Cancer - Pipeline by DiaMedica Inc., H1 2015 92 Gastric Cancer - Pipeline by Dong-A Socio Group, H1 2015 93 Gastric Cancer - Pipeline by Eddingpharm, H1 2015 94 Gastric Cancer - Pipeline by Eli Lilly and Company, H1 2015 95 Gastric Cancer - Pipeline by Epirus Biopharmaceuticals, Inc., H1 2015 96 Gastric Cancer - Pipeline by Esperance Pharmaceuticals, Inc., H1 2015 97 Gastric Cancer - Pipeline by Exelixis, Inc., H1 2015 98 Gastric Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 99 Gastric Cancer - Pipeline by Five Prime Therapeutics, Inc., H1 2015 100 Gastric Cancer - Pipeline by Galaxy Biotech, LLC, H1 2015 101 Gastric Cancer - Pipeline by Galena Biopharma, Inc., H1 2015 102 Gastric Cancer - Pipeline by Genentech, Inc., H1 2015 103 Gastric Cancer - Pipeline by GlaxoSmithKline plc, H1 2015 104 Gastric Cancer - Pipeline by GlycoNex Inc., H1 2015 105 Gastric Cancer - Pipeline by Glycotope GmbH, H1 2015 106 Gastric Cancer - Pipeline by Green Cross Corporation, H1 2015 107 Gastric Cancer - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2015 108 Gastric Cancer - Pipeline by Hutchison MediPharma Limited, H1 2015 109 Gastric Cancer - Pipeline by ImmunoGen, Inc., H1 2015 110 Gastric Cancer - Pipeline by Immunomedics, Inc., H1 2015 111 Gastric Cancer - Pipeline by Imugene Limited, H1 2015 112 Gastric Cancer - Pipeline by Incuron, LLC, H1 2015 113 Gastric Cancer - Pipeline by Incyte Corporation, H1 2015 114 Gastric Cancer - Pipeline by INSYS Therapeutics, Inc., H1 2015 115 Gastric Cancer - Pipeline by Intezyne, Inc, H1 2015 116 Gastric Cancer - Pipeline by ISU ABXIS Co.,Ltd., H1 2015 117 Gastric Cancer - Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H1 2015 118 Gastric Cancer - Pipeline by Jiangsu Kanion Pharmaceutical Co., Ltd., H1 2015 119 Gastric Cancer - Pipeline by Kadmon Corporation, LLC, H1 2015 120 Gastric Cancer - Pipeline by Karyopharm Therapeutics, Inc., H1 2015 121 Gastric Cancer - Pipeline by Kinex Pharmaceuticals, LLC, H1 2015 122 Gastric Cancer - Pipeline by Kuhnil Pharmaceutical Co., Ltd., H1 2015 123 Gastric Cancer - Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2015 124 Gastric Cancer - Pipeline by Les Laboratoires Servier SAS, H1 2015 125 Gastric Cancer - Pipeline by MacroGenics, Inc., H1 2015 126 Gastric Cancer - Pipeline by Mebiopharm Co., Ltd., H1 2015 127 Gastric Cancer - Pipeline by Merck & Co., Inc., H1 2015 128 Gastric Cancer - Pipeline by Merck KGaA, H1 2015 129 Gastric Cancer - Pipeline by Mersana Therapeutics, Inc., H1 2015 130 Gastric Cancer - Pipeline by Millennium Pharmaceuticals, Inc., H1 2015 131 Gastric Cancer - Pipeline by Molecular Targeting Technologies, Inc., H1 2015 132 Gastric Cancer - Pipeline by MSM Protein Technologies, Inc., H1 2015 133 Gastric Cancer - Pipeline by NanoCarrier Co., Ltd., H1 2015 134 Gastric Cancer - Pipeline by NeoPharm Co., Ltd., H1 2015 135 Gastric Cancer - Pipeline by Novartis AG, H1 2015 136 Gastric Cancer - Pipeline by Omnitura Therapeutics Inc., H1 2015 137 Gastric Cancer - Pipeline by OncoTherapy Science, Inc., H1 2015 138 Gastric Cancer - Pipeline by Oncothyreon Inc., H1 2015 139 Gastric Cancer - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2015 140 Gastric Cancer - Pipeline by Panacea Biotec Limited, H1 2015 141 Gastric Cancer - Pipeline by Patrys Limited, H1 2015 142 Gastric Cancer - Pipeline by Pfizer Inc., H1 2015 143 Gastric Cancer - Pipeline by Pharmacyclics, Inc., H1 2015 144 Gastric Cancer - Pipeline by Priaxon AG, H1 2015 145 Gastric Cancer - Pipeline by Regulon Inc., H1 2015 146 Gastric Cancer - Pipeline by Rexahn Pharmaceuticals, Inc., H1 2015 147 Gastric Cancer - Pipeline by Richter Gedeon Nyrt., H1 2015 148 Gastric Cancer - Pipeline by Sanofi, H1 2015 149 Gastric Cancer - Pipeline by Sareum Holdings plc, H1 2015 150 Gastric Cancer - Pipeline by SentoClone International AB, H1 2015 151 Gastric Cancer - Pipeline by Sequella, Inc., H1 2015 152 Gastric Cancer - Pipeline by Siena Biotech S.p.A., H1 2015 153 Gastric Cancer - Pipeline by Sorrento Therapeutics, Inc., H1 2015 154 Gastric Cancer - Pipeline by Sunesis Pharmaceuticals, Inc., H1 2015 155 Gastric Cancer - Pipeline by Supratek Pharma Inc., H1 2015 156 Gastric Cancer - Pipeline by Synta Pharmaceuticals Corp., H1 2015 157 Gastric Cancer - Pipeline by Synthon Holdings BV, H1 2015 158 Gastric Cancer - Pipeline by Taiho Pharmaceutical Co., Ltd., H1 2015 159 Gastric Cancer - Pipeline by Tesaro, Inc., H1 2015 160 Gastric Cancer - Pipeline by Vaxon Biotech, H1 2015 161 Gastric Cancer - Pipeline by Zymeworks Inc., H1 2015 162 Assessment by Monotherapy Products, H1 2015 163 Assessment by Combination Products, H1 2015 164 Number of Products by Stage and Target, H1 2015 166 Number of Products by Stage and Mechanism of Action, H1 2015 174 Number of Products by Stage and Route of Administration, H1 2015 180 Number of Products by Stage and Molecule Type, H1 2015 182 Gastric Cancer Therapeutics - Recent Pipeline Updates, H1 2015 475 Gastric Cancer - Dormant Projects, H1 2015 614 Gastric Cancer - Dormant Projects (Contd..1), H1 2015 615 Gastric Cancer - Dormant Projects (Contd..2), H1 2015 616 Gastric Cancer - Dormant Projects (Contd..3), H1 2015 617 Gastric Cancer - Dormant Projects (Contd..4), H1 2015 618 Gastric Cancer - Dormant Projects (Contd..5), H1 2015 619 Gastric Cancer - Dormant Projects (Contd..6), H1 2015 620 Gastric Cancer - Dormant Projects (Contd..7), H1 2015 621 Gastric Cancer - Discontinued Products, H1 2015 622 Gastric Cancer - Discontinued Products (Contd..1), H1 2015 623 Gastric Cancer - Discontinued Products (Contd..2), H1 2015 624
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.